{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T01:17:21Z","timestamp":1760231841910,"version":"build-2065373602"},"reference-count":44,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T00:00:00Z","timestamp":1665187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>The Italian Medicines Agency (AIFA) and the Italian Regional Health Systems have implemented measures together with data collection and analysis to improve medicines\u2019 appropriate prescription. Administrative databases represent rich Real-World Evidence (RWE) sources that may be leveraged for research purposes. Thus, such heritage may allow for appropriate prescription studies to be carried out on complex pharmaceutical molecules, as the appropriateness of prescriptions is essential both for patients\u2019 treatment and to ensure healthcare systems\u2019 sustainability. This study analyzed the appropriate monoclonal antibodies (mAbs) prescribed in psoriasis treatment across Tuscany, Italy. Data were extracted from several large administrative databases collected by the Tuscan Regional Healthcare System through record linkages. The analysis showed that over 30% of the 2020 cohort of psoriatic patients could be regarded as potentially inappropriate treated, signaling that mAbs are often prescribed as first-line treatment contrary to guidelines. Variation was observed in the appropriate prescription of mAbs, across different types of mAbs and areas. The study revealed potential inappropriate prescription, and its geographic variation should raise awareness among managers about the appropriate use of resources. Despite limitations, this could represent a pilot for future studies to evaluate the appropriate prescription of mAbs in other clinic conditions and across time.<\/jats:p>","DOI":"10.3390\/ph15101238","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T01:21:07Z","timestamp":1665364867000},"page":"1238","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Monitoring Appropriate Monoclonal Antibodies Prescribing via Administrative Data: An Application to Psoriasis"],"prefix":"10.3390","volume":"15","author":[{"given":"Elisa","family":"Guidotti","sequence":"first","affiliation":[{"name":"Management and Health Laboratory, Institute of Management and Department EMbeDS, Scuola Superiore Sant\u2019Anna, 56127 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Seghieri","sequence":"additional","affiliation":[{"name":"Management and Health Laboratory, Institute of Management and Department EMbeDS, Scuola Superiore Sant\u2019Anna, 56127 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruna","family":"Vinci","sequence":"additional","affiliation":[{"name":"Management and Health Laboratory, Institute of Management and Department EMbeDS, Scuola Superiore Sant\u2019Anna, 56127 Pisa, Italy"},{"name":"SSFO, Pharmacy Department, University of Pisa, 56126 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Borghini","sequence":"additional","affiliation":[{"name":"Management and Health Laboratory, Institute of Management and Department EMbeDS, Scuola Superiore Sant\u2019Anna, 56127 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Attanasio","sequence":"additional","affiliation":[{"name":"Drugs and Appropriateness Policy Sector, Regional Government, 50139 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2190\/ABWY-YFPA-ME5R-7BQP","article-title":"Improving the appropriateness of physician prescribing","volume":"28","author":"Lexchin","year":"1998","journal-title":"Int. J. Health Serv."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1136\/bmj.310.6984.923","article-title":"What constitutes good prescribing?","volume":"310","author":"Barber","year":"1995","journal-title":"BMJ"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40258-016-0240-7","article-title":"\u2018Appropriateness\u2019 in Italy: A \u2018Magic Word\u2019 in Pharmaceuticals?","volume":"15","author":"Garattini","year":"2017","journal-title":"Appl. Health Econ. Health Policy"},{"key":"ref_4","unstructured":"Agenzia Italiana del Farmaco (AIFA) (2022, September 01). Migliorare L\u2019appropriatezza Prescrittiva e L\u2019aderenza ai Trattamenti. I Dati AIFA e una Guida NICE, Available online: http:\/\/www.agenziafarmaco.gov.it\/content\/migliorare-l\u2019appropriatezza-prescrittiva-e-l\u2019aderenza-ai-trattamenti-i-dati-aifa-e-una-guida."},{"key":"ref_5","unstructured":"Agenzia Italiana del Farmaco (AIFA) (2022, September 01). Note AIFA, Available online: https:\/\/www.aifa.gov.it\/web\/guest\/note-aifa."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1017\/S0266462311000079","article-title":"Risk sharing agreements: What lessons from Italy?","volume":"27","author":"Garattini","year":"2011","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"ref_7","unstructured":"Agenzia Italiana del Farmaco (AIFA) (2022, September 01). Registri farmaci sottoposti a monitoraggio, Available online: https:\/\/www.aifa.gov.it\/web\/guest\/registri-farmaci-sottoposti-a-monitoraggio."},{"key":"ref_8","unstructured":"Agenzia Italiana del Farmaco (AIFA) (2022, September 01). Report Regionali Sul Consumo dei Farmaci in Italia\u2014Anno 2017, Available online: http:\/\/www.agenziafarmaco.gov.it\/content\/report-regionali-sul-consumo-dei-farmaci-italia-anno-2017."},{"key":"ref_9","first-page":"232","article-title":"An introduction to health care administrative data","volume":"68","author":"Cadarette","year":"2015","journal-title":"Can. J. Hosp. Pharm."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.15586\/jptcp.v26i2.599","article-title":"Challenges and new directions in obesity management: Lifestyle modification programs, pharmacotherapy, and bariatric surgery","volume":"26","author":"Carter","year":"2019","journal-title":"J. Popul. Ther. Clin. Pharmacol."},{"key":"ref_11","first-page":"1","article-title":"Appropriateness of outpatient antibiotic prescribing among privately insured US patients: ICD-10-CM based cross sectional study","volume":"364","author":"Chua","year":"2019","journal-title":"BMJ"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1111\/j.1532-5415.2005.53402.x","article-title":"Potentially inappropriate prescribing in elderly veterans: Are we using the wrong drug, wrong dose, or wrong duration?","volume":"53","author":"Pugh","year":"2005","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/jhm.1901","article-title":"Inappropriate prescribing of proton pump inhibitors in hospitalized patients","volume":"7","author":"Reid","year":"2012","journal-title":"J. Hosp. Med."},{"key":"ref_14","unstructured":"Agenzia Italiana del Farmaco (AIFA) (2022, September 01). L\u2019uso dei Farmaci in Italia Rapporto Nazionale Anno 2020, Available online: https:\/\/www.aifa.gov.it\/documents\/20142\/1542390\/Rapporto-OsMed-2020.pdf."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1001\/jama.294.18.2354","article-title":"Appropriate use of antimicrobial drugs: A better prescription is needed","volume":"294","author":"Weber","year":"2005","journal-title":"J. Am. Med. Assoc."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1177\/1461444810365020","article-title":"Review Article: TREATMENT OF PSORIASIS","volume":"11","author":"Kilmer","year":"2010","journal-title":"Journalism"},{"key":"ref_17","first-page":"169","article-title":"Safety profile and practical considerations of monoclonal antibody treatment","volume":"28","year":"2013","journal-title":"Neurol. (Engl. Ed.)"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4161\/mabs.1.2.7909","article-title":"Immunotoxicity of monoclonal antibodies","volume":"1","author":"Descotes","year":"2009","journal-title":"MAbs"},{"key":"ref_19","unstructured":"Agenzia Italiana del Farmaco (AIFA) (2022, September 01). L\u2019uso dei Farmaci in Italia\u2014Rapporto Nazionale Anno 2014. Published Online First: 2014, Available online: https:\/\/www.aifa.gov.it\/documents\/20142\/241052\/rapporto_osmed_2014_accessibile_0.pdf."},{"key":"ref_20","unstructured":"Agenzia Italiana del Farmaco (AIFA) (2022, September 01). L\u2019uso dei Farmaci in Italia\u2014Rapporto Nazionale Anno 2015. Published Online First: 2015, Available online: https:\/\/www.aifa.gov.it\/-\/rapporto-osmed-2015-consumo-e-spesa-per-eta-e-genere."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/cpt.946","article-title":"Harnessing the Power of Real-World Evidence (RWE): A Checklist to Ensure Regulatory-Grade Data Quality","volume":"103","author":"Miksad","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_22","unstructured":"Degli Esposti, L., Perrone, V., Sangiorgi, D., and Sinigaglia, L. (2021). Stima dei pazienti affetti da artrite reumatoide eleggibili al trattamento con farmaci biotecnologici e del loro consumo di risorse sanitarie e relativi costi. Reumatismo."},{"key":"ref_23","unstructured":"Emilia-romagna, R. (2022, September 01). Trattamento Sistemico Della Psoriasi Cronica a Placche Moderata-Grave. Available online: https:\/\/salute.regione.emilia-romagna.it\/ssr\/strumenti-e-informazioni\/ptr\/elaborati\/94-linee-guida-psoriasi."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/acr.22783","article-title":"2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Care Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.40726","article-title":"Special Article: 2018 American College of Rheumatology\/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.2165\/11318890-000000000-00000","article-title":"Interventions that can Reduce Inappropriate Prescribing in the Elderly: A Systematic Review","volume":"26","author":"Kaur","year":"2009","journal-title":"Drugs Aging"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrd3003","article-title":"The safety and side effects of monoclonal antibodies","volume":"9","author":"Hansel","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1080\/09546634.2019.1610553","article-title":"Anti-TNF biosimilars in psoriasis: From scientific evidence to real-world experience","volume":"31","author":"Barker","year":"2020","journal-title":"J. Dermatol. Treat."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1080\/14712598.2018.1479738","article-title":"Limitations of current monoclonal antibodies for plaque-type psoriasis and an outlook for the future","volume":"18","author":"Raimondo","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_30","first-page":"527","article-title":"Dosing frequency and medication adherence in chronic disease","volume":"18","author":"Coleman","year":"2012","journal-title":"J. Manag. Care Pharm."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2147\/PPA.S44646","article-title":"Impact of reducing dosing frequency on adherence to oral therapies: A literature review and meta-analysis","volume":"7","author":"Sadosky","year":"2013","journal-title":"Patient Prefer. Adherence"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/ajim.20655","article-title":"Geographic variation in opioid prescribing for acute, work-related, low back pain and associated factors:A multilevel analysis","volume":"52","author":"Webster","year":"2009","journal-title":"Am. J. Ind. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1001\/archinternmed.2012.3717","article-title":"Geographic variation in outpatient antibiotic prescribing among older adults","volume":"172","author":"Zhang","year":"2012","journal-title":"Arch. Intern. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.drugalcdep.2018.04.011","article-title":"Geographic variation in postpartum prescription opioid use: Opportunities to improve maternal safety","volume":"188","author":"Becker","year":"2018","journal-title":"Drug Alcohol Depend."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/jep.13181","article-title":"Unwarranted clinical variation in health care: Definitions and proposal of an analytic framework","volume":"26","author":"Sutherland","year":"2020","journal-title":"J. Eval. Clin. Pract."},{"key":"ref_36","first-page":"45","article-title":"Patient, physician and organizational influences on variation in antipsychotic prescribing behavior","volume":"19","author":"Tang","year":"2016","journal-title":"J. Ment. Health Policy Econ."},{"key":"ref_37","unstructured":"Fantini, M.P., Nuti, S., and Vola, F. (2016). Il Governo Dell\u2019innovazione Farmaceutica in Italia. Dallo Stato Dell\u2019arte a Un Modello Di Gestione Regionale Equa e Sostenibile Dei Farmaci Innovativi e Ad Alto Costo, Del Gallo Editore."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1108\/MD-09-2017-0907","article-title":"Let\u2019s play the patients music: A new generation of performance measurement systems in healthcare","volume":"56","author":"Nuti","year":"2018","journal-title":"Manag. Decis."},{"key":"ref_39","first-page":"464","article-title":"Real-world evidence: Promise and peril for medical product evaluation","volume":"43","author":"Dhruva","year":"2018","journal-title":"Pharm. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jaad.2018.06.056","article-title":"Psoriasis: Which therapy for which patient","volume":"80","author":"Kaushik","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/1346-8138.15196","article-title":"Japanese guidance for use of biologics for psoriasis (the 2019 version)","volume":"47","author":"Saeki","year":"2020","journal-title":"J. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e14290","DOI":"10.1111\/ijcp.14290","article-title":"An updated guide in the management of psoriasis for every practitioner","volume":"75","author":"Timis","year":"2021","journal-title":"Int. J. Clin. Pract."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.healthpol.2008.10.012","article-title":"Governing decentralization in health care under tough budget constraint: What can we learn from the Italian experience?","volume":"90","author":"Tediosi","year":"2009","journal-title":"Health Policy"},{"key":"ref_44","unstructured":"NIH-National Cancer Institute (2022, September 01). Second-Line Therapy, Available online: https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/second-line-therapy."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/10\/1238\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:48:21Z","timestamp":1760143701000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/10\/1238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,8]]},"references-count":44,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["ph15101238"],"URL":"https:\/\/doi.org\/10.3390\/ph15101238","relation":{},"ISSN":["1424-8247"],"issn-type":[{"type":"electronic","value":"1424-8247"}],"subject":[],"published":{"date-parts":[[2022,10,8]]}}}